anti-FGF23 antibody

An anti-FGF23 antibody is a monoclonal antibody designed to target and neutralize fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphate and vitamin D homeostasis. By binding to circulating FGF23, these antibodies inhibit its interaction with the FGF receptor 1 (FGFR1) and its co-receptor alpha-Klotho in the kidneys. This blockade prevents renal phosphate wasting, thereby increasing serum phosphate levels and active vitamin D (1,25-dihydroxyvitamin D) synthesis. Anti-FGF23 antibodies, such as the approved drug burosumab (KRN23) and the investigational candidate KK8123, are primarily developed for the treatment of FGF23-mediated hypophosphatemic disorders, including X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Additionally, preclinical research has explored their potential in mitigating bone pathology and tumor growth in multiple myeloma.

Other names

anti-FGF23 monoclonal antibodyanti-FGF-23 monoclonal antibodyanti-FGF 23 monoclonal antibodyFGF23 antibodyFGF-23 antibodyFGF 23 antibodyFGF23 monoclonal antibodyFGF-23 monoclonal antibodyFGF 23 monoclonal antibodyfibroblast growth factor 23 antibody